Skip to main content

Multiple Myeloma

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd), Autologous Transplantation, and MRD Response–Adapted Treatment Modification in NDMM

Updated Results from the CARTITUDE-1 Study of Ciltacabtagene Autoleucel CAR T-Cell Therapy in RRMM

Updated Analysis of the GRIFFIN Trial of Daratumumab plus RVd in Transplant-Eligible NDMM

Meeting Highlights

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma

Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death

Abstract #CT13

In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study

Abstract #CT08

Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study

Abstract #CT04

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone

Abstract #CT02

3
4
5
6
7
8
9

Page 6 of 11
Results 51 - 60 of 104